Literature DB >> 9307263

Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force.

R Rudick1, J Antel, C Confavreux, G Cutter, G Ellison, J Fischer, F Lublin, A Miller, J Petkau, S Rao, S Reingold, K Syndulko, A Thompson, J Wallenberg, B Weinshenker, E Willoughby.   

Abstract

This article provides recommendations from the National Multiple Sclerosis Society's Clinical Outcomes Assessment Task Force. The Task Force was appointed in 1994 and charged with recommendending improved approaches for clinical outcomes assessment in future controlled clinical trials. The recommendations herein follow extensive deliberation and data analysis during 2.5 years. General principles and desirable measurement attributes were used to assess alternative measurement techniques and clinical scales. On the basis of the analysis of existing multiple sclerosis (MS) data sets, a new measurement approach is proposed. The approach is based on quantitative functional composites that consist of simple quantitative measures from the major clinical dimensions of MS combined into a single score. Quantitative functional composites are likely to provide improved precision and sensitivity in future MS clinical trials. Studies necessary to further refine quantitative functional composites as useful MS clinical trial outcomes are delineated.

Entities:  

Mesh:

Year:  1997        PMID: 9307263     DOI: 10.1002/ana.410420318

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  72 in total

1.  European validation of a standardized clinical description of multiple sclerosis.

Authors:  Maria Pia Amato; Jerome Grimaud; Iuliana Achiti; Maria Letizia Bartolozzi; Patrice Adeleine; Hans-Peter Hartung; Ludwig Kappos; Alan Thompson; Maria Trojano; Sandra Vukusic; Christian Confavreux
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

2.  Five-year longitudinal changes in quantitative spinal cord MRI in multiple sclerosis.

Authors:  Jiwon Oh; Min Chen; Kateryna Cybulsky; Suradech Suthiphosuwan; Estelle Seyman; Blake Dewey; Marie Diener-West; Peter van Zijl; Jerry Prince; Daniel S Reich; Peter A Calabresi
Journal:  Mult Scler       Date:  2020-06-01       Impact factor: 6.312

Review 3.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

4.  Determining the Presence of Reliable Change over Time in Multiple Sclerosis: Evidence from the PASAT, Adjusting-PSAT, and Stroop Test.

Authors:  Suzanne L Barker-Collo; Suzanne C Purdy
Journal:  Int J MS Care       Date:  2013

5.  Effects of a 10-week inspiratory muscle training program on lower-extremity mobility in people with multiple sclerosis: a randomized controlled trial.

Authors:  Lucinda Pfalzer; Donna Fry
Journal:  Int J MS Care       Date:  2011

6.  Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord.

Authors:  Kathleen M Zackowski; Seth A Smith; Daniel S Reich; Eliza Gordon-Lipkin; BettyAnn A Chodkowski; Divya R Sambandan; Michael Shteyman; Amy J Bastian; Peter C van Zijl; Peter A Calabresi
Journal:  Brain       Date:  2009-03-18       Impact factor: 13.501

7.  Variations in functioning and disability in multiple sclerosis. A two-year prospective study.

Authors:  Charlotte Ytterberg; Sverker Johansson; Magnus Andersson; Lotta Widén Holmqvist; Lena von Koch
Journal:  J Neurol       Date:  2008-06-17       Impact factor: 4.849

8.  Sensorimotor cortex gamma-aminobutyric acid concentration correlates with impaired performance in patients with MS.

Authors:  P K Bhattacharyya; M D Phillips; L A Stone; R A Bermel; M J Lowe
Journal:  AJNR Am J Neuroradiol       Date:  2013-03-14       Impact factor: 3.825

9.  Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29.

Authors:  Melina Ramp; Fary Khan; Rose Anne Misajon; Julie F Pallant
Journal:  Health Qual Life Outcomes       Date:  2009-06-22       Impact factor: 3.186

10.  Natalizumab for the treatment of relapsing multiple sclerosis.

Authors:  Richard A Rudick; Michael A Panzara
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.